Parkinson's disease.
Marsden
C D
CD
University Department of Clinical Neurology, National Hospital for Nervous Diseases, London, UK.
D015655:1-Methyl-4-phenylpyridinium / Q000009:adverse effects; D000311:Adrenal Glands / Q000637:transplantation; D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D001923:Brain Chemistry; D002648:Child; D002675:Child, Preschool; D003594:Cytoplasmic Granules / Q000473:pathology; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D004785:Environmental Pollutants / Q000009:adverse effects; D005333:Fetus; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010166:Palliative Care; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D015995:Prevalence; D012106:Research; D012642:Selegiline / Q000627:therapeutic use; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology / Q000637:transplantation; D013997:Time Factors
D000978:Antiparkinson Agents; D004785:Environmental Pollutants; D012642:Selegiline; D007980:Levodopa; D015655:1-Methyl-4-phenylpyridinium